TY - JOUR
T1 - Clinical history of cancer-associated splanchnic vein thrombosis
AU - Valeriani, Emanuele
AU - di Nisio, Marcello
AU - Riva, Nicoletta
AU - Caiano, Lucia Maria
AU - Porreca, Ettore
AU - Bang, Soo-Mee
AU - Beyer-Westendorf, Jan
AU - Sartori, Maria Teresa
AU - Barillari, Giovanni
AU - Santoro, Rita
AU - Kamphuisen, Pieter W.
AU - Alatri, Adriano
AU - Malato, Alessandra
AU - Vidili, Gianpaolo
AU - Oh, Doyeun
AU - International Registry on Splanchnic Vein Thrombosis (IRSVT) study group
AU - Schulman, Sam
AU - Ageno, Walter
N1 - Funding Information: This study was promoted through the International Society on Thrombosis and Haemostasis and was supported by a research grant from Pfizer Canada. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. There was no other funding source for this study. Funding Information: Dr. Di Nisio reports personal fees from Bayer, Daiichi Sankyo, BMS‐Pfizer, Leo Pharma, Sanofi, and Aspen, outside the submitted work; Dr. Sartori reports personal fees from Bayer and Daiichi Sankyo outside the submitted work; Dr. Beyer‐Westendorf received honoraria and institutional research support from Bayer HealthCare, Boehringer Ingelheim, BMS/Pfizer, CSL Behring, Daiichi Sankyo, and LEO Pharma; Dr. Ageno has received a research grant from Bayer to support a clinical study in patients with splanchnic vein thrombosis, received honoraria for participation at advisory boards from Bayer, Boehringer Inghelheim, Daiichi Sankyo, BMS/Pfizer, Sanofi, and Portola, and reports grants and personal fees from Bayer, and personal fees from BMS/Pfizer, Daiichi Sankyo, Sanofi, Aspen, Janssen, and Portola, outside the submitted work. Drs. Valeriani, Riva, Caiano, Porreca, Bang, Barillari, Santoro, Kamphuisen, Alatri, Malato, Vidili, Oh, and Schulman have nothing to disclose. Publisher Copyright: © 2020 International Society on Thrombosis and Haemostasis
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Background: Cancer represents a risk factor for splanchnic vein thrombosis (SVT) and usual site venous thromboembolism (VTE). Objectives: To compare characteristics and outcomes of patients with cancer-associated SVT and usual site VTE. Patients/Methods: Patients with solid cancer and SVT were enrolled in an international, prospective registry between May 2008 and January 2012. The comparison cohort included (1:1 ratio) patients with solid cancer and usual site VTE treated at two thrombosis centers who had a minimum of 12 months follow-up at December 2019 or experienced one of the outcomes within 12 months follow-up. Recurrent VTE, major bleeding, and all-cause mortality were evaluated at 12-month follow-up. Results: A total of 264 patients (132 in each cohort) were enrolled. Patients with SVT were less likely to have metastatic disease (36.1% vs 72.5%) or receive cancer therapy at thrombosis diagnosis (29.6% vs 64.9%). The most frequent cancer types were hepatobiliary and pancreatic in the SVT cohort and gastrointestinal in the usual site VTE cohort. Fewer patients with SVT received anticoagulation (68.9% vs 99.2%), and treatment duration was shorter (6.0 vs 11.0 months). The cumulative incidence of major bleeding (2.3% vs 4.7%) was nonsignificantly lower in the SVT cohort, whereas recurrent thrombosis (4.7% vs 5.5%) and all-cause mortality (41.7% vs 39.4%) were comparable between the two cohorts. Conclusions: The risk of recurrent thrombosis and bleeding appears to be similar in cancer patients with SVT and cancer patients with usual site VTE, despite some differences in baseline characteristics and anticoagulant treatment. Further prospective studies are warranted to confirm these findings.
AB - Background: Cancer represents a risk factor for splanchnic vein thrombosis (SVT) and usual site venous thromboembolism (VTE). Objectives: To compare characteristics and outcomes of patients with cancer-associated SVT and usual site VTE. Patients/Methods: Patients with solid cancer and SVT were enrolled in an international, prospective registry between May 2008 and January 2012. The comparison cohort included (1:1 ratio) patients with solid cancer and usual site VTE treated at two thrombosis centers who had a minimum of 12 months follow-up at December 2019 or experienced one of the outcomes within 12 months follow-up. Recurrent VTE, major bleeding, and all-cause mortality were evaluated at 12-month follow-up. Results: A total of 264 patients (132 in each cohort) were enrolled. Patients with SVT were less likely to have metastatic disease (36.1% vs 72.5%) or receive cancer therapy at thrombosis diagnosis (29.6% vs 64.9%). The most frequent cancer types were hepatobiliary and pancreatic in the SVT cohort and gastrointestinal in the usual site VTE cohort. Fewer patients with SVT received anticoagulation (68.9% vs 99.2%), and treatment duration was shorter (6.0 vs 11.0 months). The cumulative incidence of major bleeding (2.3% vs 4.7%) was nonsignificantly lower in the SVT cohort, whereas recurrent thrombosis (4.7% vs 5.5%) and all-cause mortality (41.7% vs 39.4%) were comparable between the two cohorts. Conclusions: The risk of recurrent thrombosis and bleeding appears to be similar in cancer patients with SVT and cancer patients with usual site VTE, despite some differences in baseline characteristics and anticoagulant treatment. Further prospective studies are warranted to confirm these findings.
KW - anticoagulants
KW - mesenteric veins
KW - neoplasms
KW - portal vein
KW - splanchnic circulation
UR - http://www.scopus.com/inward/record.url?scp=85100886128&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/jth.15214
DO - https://doi.org/10.1111/jth.15214
M3 - Article
C2 - 33306241
SN - 1538-7933
VL - 19
SP - 983
EP - 991
JO - Journal of thrombosis and haemostasis
JF - Journal of thrombosis and haemostasis
IS - 4
ER -